Skip to main content
Top
Published in: Cardiovascular Ultrasound 1/2014

Open Access 01-12-2014 | Research

Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease

Authors: Nicoline Jochmann, Franziska Schröter, Fabian Knebel, Robert Hättasch, Christine Gericke, Karl Stangl, Gert Baumann, Verena Stangl

Published in: Cardiovascular Ultrasound | Issue 1/2014

Login to get access

Abstract

Background

Experimental data suggests that exclusive heart rate reduction with ivabradine is associated with the amelioration of the endothelial function. Since it is presently unknown whether this also applies to humans, the aim of this pilot study was to investigate whether heart rate reduction with ivabradine modulates the endothelial function in humans with an established coronary heart disease.

Methods

Using high-sensitivity ultrasound, we analysed the flow-mediated (FMD) and nitro-mediated dilation (NMD) of the brachial artery in 25 patients (62.9 ± 8.4 years) with a stable coronary heart disease and a resting heart rate of ≥70 beats per minute (bpm). To assess acute effects, measurements were performed before and 4 hours after the first intake of ivabradine 7.5 mg. Sustained effects of an ivabradine therapy (5 mg to 7.5 mg twice daily) were investigated after 4 weeks.

Results

We found a significant decrease in heart rate, both 4 hours after the intake of 7.5 mg of ivabradine (median -8 [interquartile range (IQR) -14 to -4] bpm) and after 4 weeks of twice daily intake (median -10 [IQR-17 to -5] bpm) (p < 0.05). However, the FMD did not change significantly: neither after first dose of ivabradine nor after sustained therapy (baseline FMD: median 5.0 [IQR 2.4 to 7.9]%; FMD 4 hours after 7.5 mg of ivabradine: median 4.9 [IQR 2.7 to 9.8]%; FMD after 4 weeks of ivabradine therapy: median 6.1 [IQR 4.3 to 8.2]%). No significant changes of the NMD were observed. In regression analysis, the heart rate and FMD did not correlated, irrespective of the ivabradine intake (r2 = 0.086).

Conclusion

In conclusion, in our study heart rate reduction through ivabradine does not improve the endothelial function in patients with a stable coronary heart disease. Moreover, we found no correlation between the heart rate and the endothelial function.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kannel WB, Kannel C, Paffenbarger RS, Cupples LA: Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987, 113 (6): 1489-1494. 10.1016/0002-8703(87)90666-1.CrossRefPubMed Kannel WB, Kannel C, Paffenbarger RS, Cupples LA: Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987, 113 (6): 1489-1494. 10.1016/0002-8703(87)90666-1.CrossRefPubMed
2.
go back to reference Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J: Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990, 65 (9): 547-553. 10.1016/0002-9149(90)91029-6.CrossRefPubMed Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J: Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol. 1990, 65 (9): 547-553. 10.1016/0002-9149(90)91029-6.CrossRefPubMed
3.
go back to reference Diaz A, Bourassa MG, Guertin MC, Tardif JC: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005, 26 (10): 967-974. 10.1093/eurheartj/ehi190.CrossRefPubMed Diaz A, Bourassa MG, Guertin MC, Tardif JC: Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J. 2005, 26 (10): 967-974. 10.1093/eurheartj/ehi190.CrossRefPubMed
4.
go back to reference Gillman MW, Kannel WB, Belanger A, D’Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993, 125 (4): 1148-1154. 10.1016/0002-8703(93)90128-V.CrossRefPubMed Gillman MW, Kannel WB, Belanger A, D’Agostino RB: Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993, 125 (4): 1148-1154. 10.1016/0002-8703(93)90128-V.CrossRefPubMed
5.
go back to reference Fox KM, Ferrari R: Heart rate: a forgotten link in coronary artery disease?. Nat Rev Cardiol. 2011, 8 (7): 369-379. 10.1038/nrcardio.2011.58.CrossRefPubMed Fox KM, Ferrari R: Heart rate: a forgotten link in coronary artery disease?. Nat Rev Cardiol. 2011, 8 (7): 369-379. 10.1038/nrcardio.2011.58.CrossRefPubMed
6.
7.
go back to reference Custodis F, Reil JC, Laufs U, Bohm M: [Heart rate and rate control: prognostic value in cardiovascular diseases]. Internist. 2012, 53 (1): 6-13. 10.1007/s00108-011-2887-3.CrossRefPubMed Custodis F, Reil JC, Laufs U, Bohm M: [Heart rate and rate control: prognostic value in cardiovascular diseases]. Internist. 2012, 53 (1): 6-13. 10.1007/s00108-011-2887-3.CrossRefPubMed
8.
go back to reference Custodis F, Baumhakel M, Schlimmer N, List F, Gensch C, Bohm M, Laufs U: Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008, 117 (18): 2377-2387. 10.1161/CIRCULATIONAHA.107.746537.CrossRefPubMed Custodis F, Baumhakel M, Schlimmer N, List F, Gensch C, Bohm M, Laufs U: Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008, 117 (18): 2377-2387. 10.1161/CIRCULATIONAHA.107.746537.CrossRefPubMed
9.
go back to reference Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC: Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008, 154 (4): 749-757.CrossRefPubMedPubMedCentral Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC: Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008, 154 (4): 749-757.CrossRefPubMedPubMedCentral
10.
go back to reference Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M: Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis. 2010, 212 (1): 55-62. 10.1016/j.atherosclerosis.2010.03.002.CrossRefPubMed Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M: Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis. 2010, 212 (1): 55-62. 10.1016/j.atherosclerosis.2010.03.002.CrossRefPubMed
11.
go back to reference Lavrencic A, Salobir BG, Keber I: Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol. 2000, 20 (2): 551-555. 10.1161/01.ATV.20.2.551.CrossRefPubMed Lavrencic A, Salobir BG, Keber I: Physical training improves flow-mediated dilation in patients with the polymetabolic syndrome. Arterioscler Thromb Vasc Biol. 2000, 20 (2): 551-555. 10.1161/01.ATV.20.2.551.CrossRefPubMed
12.
go back to reference Green D, Cheetham C, Henderson C, Weerasooriya R, O’Driscoll G: Effect of cardiac pacing on forearm vascular responses and nitric oxide function. Am J Physiol Heart Circ Physiol. 2002, 283 (4): H1354-H1360.CrossRefPubMed Green D, Cheetham C, Henderson C, Weerasooriya R, O’Driscoll G: Effect of cardiac pacing on forearm vascular responses and nitric oxide function. Am J Physiol Heart Circ Physiol. 2002, 283 (4): H1354-H1360.CrossRefPubMed
13.
go back to reference Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF, Lehman BT, Fan S, Osypiuk E, Vita JA: Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation. 2004, 109 (5): 613-619. 10.1161/01.CIR.0000112565.60887.1E.CrossRefPubMed Benjamin EJ, Larson MG, Keyes MJ, Mitchell GF, Vasan RS, Keaney JF, Lehman BT, Fan S, Osypiuk E, Vita JA: Clinical correlates and heritability of flow-mediated dilation in the community: the Framingham Heart Study. Circulation. 2004, 109 (5): 613-619. 10.1161/01.CIR.0000112565.60887.1E.CrossRefPubMed
14.
go back to reference Mizia M, Mizia-Stec K, Gasior Z, Gomulka S, Kumor P, Niedojadlo A, Mielczarek M: Mental stress, heart rate and endothelial function in patients with syndrome X. Cardiol J. 2007, 14 (2): 180-185.PubMed Mizia M, Mizia-Stec K, Gasior Z, Gomulka S, Kumor P, Niedojadlo A, Mielczarek M: Mental stress, heart rate and endothelial function in patients with syndrome X. Cardiol J. 2007, 14 (2): 180-185.PubMed
15.
go back to reference Camm AJ, Lau CP: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D. 2003, 4 (2): 83-89. 10.2165/00126839-200304020-00001.CrossRef Camm AJ, Lau CP: Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs R&D. 2003, 4 (2): 83-89. 10.2165/00126839-200304020-00001.CrossRef
16.
go back to reference Manz M, Reuter M, Lauck G, Omran H, Jung W: A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003, 100 (3): 149-155. 10.1159/000073933.CrossRefPubMed Manz M, Reuter M, Lauck G, Omran H, Jung W: A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003, 100 (3): 149-155. 10.1159/000073933.CrossRefPubMed
17.
go back to reference Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006, 61 (2): 127-137. 10.1111/j.1365-2125.2005.02544.x.CrossRefPubMed Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C: Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006, 61 (2): 127-137. 10.1111/j.1365-2125.2005.02544.x.CrossRefPubMed
18.
go back to reference Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, et al.: European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33 (13): 1635-1701.CrossRefPubMed Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, et al.: European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012, 33 (13): 1635-1701.CrossRefPubMed
19.
go back to reference Lorenz M, Jochmann N, von Krosigk A, Martus P, Baumann G, Stangl K, Stangl V: Addition of milk prevents vascular protective effects of tea. Eur Heart J. 2007, 28 (2): 219-223.CrossRefPubMed Lorenz M, Jochmann N, von Krosigk A, Martus P, Baumann G, Stangl K, Stangl V: Addition of milk prevents vascular protective effects of tea. Eur Heart J. 2007, 28 (2): 219-223.CrossRefPubMed
20.
go back to reference Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002, 39 (2): 257-265. 10.1016/S0735-1097(01)01746-6.CrossRefPubMed Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002, 39 (2): 257-265. 10.1016/S0735-1097(01)01746-6.CrossRefPubMed
21.
go back to reference Pyke KE, Tschakovsky ME: The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol. 2005, 568 (Pt 2): 357-369.CrossRefPubMedPubMedCentral Pyke KE, Tschakovsky ME: The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function. J Physiol. 2005, 568 (Pt 2): 357-369.CrossRefPubMedPubMedCentral
22.
go back to reference Nerla R, Di Franco A, Milo M, Pitocco D, Zaccardi F, Tarzia P, Sarullo FM, Villano A, Russo G, Stazi A, et al.: Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart. 2012, 98 (24): 1812-1816. 10.1136/heartjnl-2012-302795.CrossRefPubMed Nerla R, Di Franco A, Milo M, Pitocco D, Zaccardi F, Tarzia P, Sarullo FM, Villano A, Russo G, Stazi A, et al.: Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients. Heart. 2012, 98 (24): 1812-1816. 10.1136/heartjnl-2012-302795.CrossRefPubMed
23.
go back to reference Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Maria F, Gaetano S, et al.: Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013, 112 (1): 8-13. 10.1016/j.amjcard.2013.02.045.CrossRefPubMed Villano A, Di Franco A, Nerla R, Sestito A, Tarzia P, Lamendola P, Di Monaco A, Maria F, Gaetano S, et al.: Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013, 112 (1): 8-13. 10.1016/j.amjcard.2013.02.045.CrossRefPubMed
24.
go back to reference Schirmer SH, Degen A, Baumhakel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, et al.: Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J. 2012, 33 (10): 1223-1231. 10.1093/eurheartj/ehr255.CrossRefPubMed Schirmer SH, Degen A, Baumhakel M, Custodis F, Schuh L, Kohlhaas M, Friedrich E, Bahlmann F, Kappl R, Maack C, et al.: Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur Heart J. 2012, 33 (10): 1223-1231. 10.1093/eurheartj/ehr255.CrossRefPubMed
25.
go back to reference Harzheim D, Pfeiffer KH, Fabritz L, Kremmer E, Buch T, Waisman A, Kirchhof P, Kaupp UB, Seifert R: Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. EMBO J. 2008, 27 (4): 692-703. 10.1038/emboj.2008.3.CrossRefPubMedPubMedCentral Harzheim D, Pfeiffer KH, Fabritz L, Kremmer E, Buch T, Waisman A, Kirchhof P, Kaupp UB, Seifert R: Cardiac pacemaker function of HCN4 channels in mice is confined to embryonic development and requires cyclic AMP. EMBO J. 2008, 27 (4): 692-703. 10.1038/emboj.2008.3.CrossRefPubMedPubMedCentral
26.
go back to reference Triggle CR: Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. Br J Pharmacol. 2008, 154 (4): 727-728.CrossRefPubMedPubMedCentral Triggle CR: Defying the economists: a decrease in heart rate improves not only cardiac but also endothelial function. Br J Pharmacol. 2008, 154 (4): 727-728.CrossRefPubMedPubMedCentral
Metadata
Title
Effect of ivabradine-induced heart rate reduction on flow-mediated dilation measured with high-sensitivity ultrasound in patients with stable coronary heart disease
Authors
Nicoline Jochmann
Franziska Schröter
Fabian Knebel
Robert Hättasch
Christine Gericke
Karl Stangl
Gert Baumann
Verena Stangl
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Ultrasound / Issue 1/2014
Electronic ISSN: 1476-7120
DOI
https://doi.org/10.1186/1476-7120-12-5

Other articles of this Issue 1/2014

Cardiovascular Ultrasound 1/2014 Go to the issue

How I do it article

How I do it: Lung ultrasound

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.